SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:lup.lub.lu.se:2915b32d-b76b-4f0c-8d00-cfaeb67840b8"
 

Sökning: onr:"swepub:oai:lup.lub.lu.se:2915b32d-b76b-4f0c-8d00-cfaeb67840b8" > Serum proteome modu...

  • Lokhande, LavanyaLund University,Lunds universitet,Institutionen för immunteknologi,Institutioner vid LTH,Lunds Tekniska Högskola,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Department of Immunotechnology,Departments at LTH,Faculty of Engineering, LTH,LUCC: Lund University Cancer Centre,Other Strong Research Environments (författare)

Serum proteome modulations upon treatment provides biological insight on response to treatment in relapsed mantle cell lymphoma

  • Artikel/kapitelEngelska2022

Förlag, utgivningsår, omfång ...

  • 2021-07-28
  • Wiley,2022

Nummerbeteckningar

  • LIBRIS-ID:oai:lup.lub.lu.se:2915b32d-b76b-4f0c-8d00-cfaeb67840b8
  • https://lup.lub.lu.se/record/2915b32d-b76b-4f0c-8d00-cfaeb67840b8URI
  • https://doi.org/10.1002/cnr2.1524DOI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:art swepub-publicationtype
  • Ämneskategori:ref swepub-contenttype

Anmärkningar

  • Background: The possibility to monitor patient's serum proteome during treatment can provide deepened understanding of the biology associated with response to specific drugs. Non-invasive serum sampling provides an opportunity for sustainable repetitive sampling of patients, which allows for more frequent evaluation of the biological response and enhanced flexibility in treatment selection in contrast to tissue biopsies. Aim: To pin-point biologically relevant changes in pre- and on-treatment serum proteome samples in relapsed mantle cell lymphoma (MCL) patients, leading to insight into mechanisms behind response to treatment in sub-groups of patients. Methods: Pre- and on-treatment serum samples from relapsed MCL patients treated with a triple combination therapy of rituximab, ibrutinib and lenalidomide were available for the study, together with detailed clinicopathological information. A microarray technology targeting 158 serum proteins using 371 antibody-fragments was used to compare the serum proteome at the two time-points. Results: Proteins modulated by the treatment were shown to be associated to a MCL sub-group with ATM/TP53 alterations, which emphasizes the importance of treatment stratification. Absolute values of serum protein levels in on-treatment samples were highly variable and showed no correlation to outcome. To circumvent the challenge of variability in absolute serum protein levels, the velocity of change of individual serum proteins was used to identify proteins associated with clinical response. Increased values of TGF-β1, CD40 and complement component 4 comparing pre- and on-treatment samples were associated with remaining minimal residual disease (MRD) and increased BTK was associated with short progression-free survival (PFS). Conclusion: We show that the genetic sub-type of MCL affects the biological response to treatment in serum and that the change in defined serum proteins reveals the biology associated with clinical response.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Kuci Emruli, VeneraLund University,Lunds universitet,Institutionen för immunteknologi,Institutioner vid LTH,Lunds Tekniska Högskola,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Department of Immunotechnology,Departments at LTH,Faculty of Engineering, LTH,LUCC: Lund University Cancer Centre,Other Strong Research Environments(Swepub:lu)immu-vku (författare)
  • Eskelund, Christian WintherUniversity of Copenhagen,Copenhagen University Hospital (författare)
  • Kolstad, ArneOslo university hospital (författare)
  • Hutchings, MartinCopenhagen University Hospital (författare)
  • Räty, RiikkaHelsinki University Central Hospital (författare)
  • Niemann, Carsten UtoftUniversity of Copenhagen (författare)
  • Grønbæk, KirstenCopenhagen University Hospital,University of Copenhagen (författare)
  • Jerkeman, MatsLund University,Lunds universitet,Medicinsk onkologi,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Medical oncology,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,LUCC: Lund University Cancer Centre,Other Strong Research Environments(Swepub:lu)onk-mje (författare)
  • Ek, SaraLund University,Lunds universitet,Institutionen för immunteknologi,Institutioner vid LTH,Lunds Tekniska Högskola,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Department of Immunotechnology,Departments at LTH,Faculty of Engineering, LTH,LUCC: Lund University Cancer Centre,Other Strong Research Environments(Swepub:lu)immt-san (författare)
  • Institutionen för immunteknologiInstitutioner vid LTH (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:Cancer Reports: Wiley5:72573-8348

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy